Access the full text.
Sign up today, get DeepDyve free for 14 days.
A. Lebeau, D. Deimling, Christine Kaltz, A. Sendelhofert, Anette Iff, Beate Luthardt, M. Untch, U. Löhrs (2001)
Her-2/neu analysis in archival tissue samples of human breast cancer: comparison of immunohistochemistry and fluorescence in situ hybridization.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 19 2
Ganoberg (2000)
Sensitivity of HER-2/neu antibodies in archival tissue samples of invasive breast carcinomas. Correlation with oncogene amplification in 160 casesAnat Pathol, 113
M. Pegram, A. Lipton, D. Hayes, B. Weber, J. Baselga, D. Tripathy, Debbie Baly, S. Baughman, T. Twaddell, J. Glaspy, D. Slamon (1998)
Phase II study of receptor-enhanced chemosensitivity using recombinant humanized anti-p185HER2/neu monoclonal antibody plus cisplatin in patients with HER2/neu-overexpressing metastatic breast cancer refractory to chemotherapy treatment.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 16 8
Perez (2002)
HER-2 testing in patients with breast cancer: poor correlation between weak positivity by immunohistochemistry and gene amplification by fluorescence in situ hybridizationMayo Clin Proc, 77
Shak (1999)
Overview of the trastuzumab (Herceptin) anti-HER2 monoclonal antibody clinical program in HER2-overexpressing metastatic breast cancerSemin Oncol, 26
B. Têtu, J. Brisson (1994)
Prognostic significance of HER‐2/neu oncoprotein expression in node‐positive breast cancer. The influence of the pattern of immunostaining and adjuvant therapyCancer, 73
R. Ridolfi, M. Jamehdor, J. Arber (2000)
HER-2/neu Testing in Breast Carcinoma: A Combined Immunohistochemical and Fluorescence In Situ Hybridization ApproachModern Pathology, 13
Sijian Wang, M. Saboorian, Eugene Frenkel, Linda Hynan, S. Gokaslan, R. Ashfaq (2000)
Laboratory assessment of the status of Her-2/neu protein and oncogene in breast cancer specimens: comparison of immunohistochemistry assay with fluorescence in situ hybridisation assaysJournal of Clinical Pathology, 53
S. Shak (1999)
Overview of the trastuzumab (Herceptin) anti-HER2 monoclonal antibody clinical program in HER2-overexpressing metastatic breast cancer. Herceptin Multinational Investigator Study Group.Seminars in oncology, 26 4 Suppl 12
P. Sampatanukul (2005)
Prognostic factors in breast cancer
D. Slamon, G. Clark, S. Wong, W. Levin, A. Ullrich, W. McGuire (1987)
Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene.Science, 235 4785
A. Seidman, M. Fornier, F. Esteva, L. Tan, Stamatina Kaptain, A. Bach, K. Panageas, C. Arroyo, V. Valero, V. Currie, T. Gilewski, M. Theodoulou, M. Moynahan, M. Moasser, N. Sklarin, M. Dickler, G. D’Andrea, M. Cristofanilli, E. Rivera, G. Hortobagyi, L. Norton, C. Hudis (2001)
Weekly trastuzumab and paclitaxel therapy for metastatic breast cancer with analysis of efficacy by HER2 immunophenotype and gene amplification.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 19 10
S. Schnitt (2001)
Breast Cancer in the 21st Century: Neu Opportunities and Neu ChallengesModern Pathology, 14
A. Bankfalvi, R. Simon, B. Brandt, H. Bürger, I. Vollmer, B. Dockhorn‐Dworniczak, R. Lelle, W. Boecker (2000)
Comparative methodological analysis of erbB‐2/HER‐2 gene dosage, chromosomal copy number and protein overexpression in breast carcinoma tissues for diagnostic useHistopathology, 37
P. Ónody, F. Bertrand, F. Muzeau, I. Bièche, R. Lidereau (2001)
Fluorescence in situ hybridization and immunohistochemical assays for HER-2/neu status determination: application to node-negative breast cancer.Archives of pathology & laboratory medicine, 125 6
A. Cianciulli, C. Botti, A. Coletta, S. Buglioni, R. Marzano, M. Benevolo, A. Cione, M. Mottolese (2002)
Contribution of fluorescence in situ hybridization to immunohistochemistry for the evaluation of HER-2 in breast cancer.Cancer genetics and cytogenetics, 133 1
T. Thomson, M. Hayes, J. Spinelli, Ernie Hilland, Christina Sawrenko, D. Phillips, B. Dupuis, Robin Parker (2001)
HER-2/neu in Breast Cancer: Interobserver Variability and Performance of Immunohistochemistry with 4 Antibodies Compared with Fluorescent In Situ HybridizationModern Pathology, 14
R. Bast, P. Ravdin, D. Hayes, Susan Bates, H. Fritsche, J. Jessup, N. Kemeny, G. Locker, R. Mennel, M. Somerfield (2001)
2000 update of recommendations for the use of tumor markers in breast and colorectal cancer: clinical practice guidelines of the American Society of Clinical Oncology.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 19 6
Frances O'Malley, Frances O'Malley, Robert Parkes, Eleanor Latta, Eleanor Latta, Suzanna Tjan, Tanya Zadro, Rosemary Mueller, Nona Arneson, M. Blackstein, I. Andrulis (2001)
Comparison of HER2/neu status assessed by quantitative polymerase chain reaction and immunohistochemistry.American journal of clinical pathology, 115 4
S. Toikkanen, H. Helin, J. Isola, H. Joensuu (1992)
Prognostic significance of HER-2 oncoprotein expression in breast cancer: a 30-year follow-up.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 10 7
D. Gancberg, L. Lespagnard, G. Rouas, M. Paesmans, M. Piccart, A. Leo, J. Nogaret, D. Hertens, A. Verhest, D. Larsimont (2000)
Sensitivity of HER-2/neu antibodies in archival tissue samples of invasive breast carcinomas. Correlation with oncogene amplification in 160 cases.American journal of clinical pathology, 113 5
W. Hanna, H. Kahn, M. Trudeau (1999)
Evaluation of HER-2/neu (erbB-2) status in breast cancer: from bench to bedside.Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc, 12 8
M. Press, L. Bernstein, P. Thomas, L. Meisner, Jian‐Yuan Zhou, Yanling Ma, G. Hung, R. Robinson, C. Harris, A. El-Naggar, D. Slamon, Richard Phillips, J. Ross, S. Wolman, K. Flom (1997)
HER-2/neu gene amplification characterized by fluorescence in situ hybridization: poor prognosis in node-negative breast carcinomas.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 15 8
A. Keshgegian, A. Cnaan (1997)
erbB-2 oncoprotein expression in breast carcinoma. Poor prognosis associated with high degree of cytoplasmic positivity using CB-11 antibody.American journal of clinical pathology, 108 4
R. Jimenez, T. Wallis, Pam Tabasczka, D. Visscher (2000)
Determination of Her-2/Neu Status in Breast Carcinoma: Comparative Analysis of Immunohistochemistry and Fluorescent In Situ HybridizationModern Pathology, 13
M. Bilous, M. Dowsett, W. Hanna, J. Isola, A. Lebeau, A. Moreno, F. Penault-Llorca, J. Rüschoff, G. Tomasic, M. Vijver (2003)
Current Perspectives on HER2 Testing: A Review of National Testing GuidelinesModern Pathology, 16
E. Perez, P. Roche, R. Jenkins, C. Reynolds, K. Halling, J. Ingle, L. Wold (2002)
HER2 testing in patients with breast cancer: poor correlation between weak positivity by immunohistochemistry and gene amplification by fluorescence in situ hybridization.Mayo Clinic proceedings, 77 2
W. Hanna, H. Kahn, Margaret Pienkowska, J. Blondal, A. Seth, Alexander Marks (2001)
Defining a Test for HER-2/neu Evaluation in Breast Cancer in the Diagnostic SettingModern Pathology, 14
Fitzgibbons (2000)
Prognostic factor in breast cancer. College of American Pathologists Consensus Statement 1999Arch Path Lab Med, 124
P. Roche, J. Ingle (1999)
Increased HER2 with U.S. Food and Drug Administration-approved antibody.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 17 1
J. Baselga, L. Gianni, C. Geyer, E. Perez, A. Riva, C. Jackisch (2004)
Future options with trastuzumab for primary systemic and adjuvant therapy.Seminars in oncology, 31 5 Suppl 10
Tubbs Rr, J. Pettay, P. Roche, M. Stoler, R. Jenkins, T. Grogan (2001)
Discrepancies in clinical laboratory testing of eligibility for trastuzumab therapy: apparent immunohistochemical false-positives do not get the message.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 19 10
N. Ratcliffe, W. Wells, K. Wheeler, V. Memoli (1997)
The combination of in situ hybridization and immunohistochemical analysis: an evaluation of Her2/neu expression in paraffin-embedded breast carcinomas and adjacent normal-appearing breast epithelium.Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc, 10 12
M. Noguchi, N. Koyasaki, N. Ohta, H. Kitagawa, M. Earashi, M. Thomas, Itsuo Miyazaki, Y. Mizukami (1992)
C‐erbb‐2 oncoprotein expression versus internal mammary lymph node metastases as additional prognostic factors in patients with axillary lymph node‐positive breast cancerCancer, 69
H. Muss, A. Thor, D. Berry, T. Kute, E. Liu, F. Koerner, C. Cirrincione, D. Budman, W. Wood, M. Barcos, I. Henderson (1994)
c-erbB-2 expression and response to adjuvant therapy in women with node-positive early breast cancer.The New England journal of medicine, 330 18
J. Couturier, A. Vincent-Salomon, A. Nicolas, P. Beuzeboc, E. Mouret, B. Zafrani, X. Sastre-Garau (2000)
Strong Correlation between Results of Fluorescent In Situ Hybridization and Immunohistochemistry for the Assessment of the ERBB2 (HER-2/neu) Gene Status in Breast CarcinomaModern Pathology, 13
(2002)
Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2overexpressing metastatic brest cancer
A. Sahin (2000)
Biologic and Clinical Significance of HER‐2/neu (cerbB‐2) in Breast CancerAdvances in Anatomic Pathology, 7
T. Jacobs, A. Gown, H. Yaziji, Melissa Barnes, S. Schnitt (1999)
Comparison of fluorescence in situ hybridization and immunohistochemistry for the evaluation of HER-2/neu in breast cancer.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 17 7
J. Baselga, D. Tripathy, J. Mendelsohn, S. Baughman, C. Benz, L. Dantis, N. Sklarin, A. Seidman, C. Hudis, J. Moore, P. Rosen, T. Twaddell, I. Henderson, L. Norton (1996)
Phase II study of weekly intravenous recombinant humanized anti-p185HER2 monoclonal antibody in patients with HER2/neu-overexpressing metastatic breast cancer.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 14 3
H. Yaziji, L. Goldstein, T. Barry, R. Werling, H. Hwang, G. Ellis, J. Gralow, R. Livingston, A. Gown (2004)
HER-2 testing in breast cancer using parallel tissue-based methods.JAMA, 291 16
ORIGINAL ARTICLE Selecting Antibodies to Detect HER2 Overexpression by Immunohistochemistry in Invasive Mammary Carcinomas Agostinho Pinto Gouveˆa, MD, PhD,* Fernanda Milanezi, MD,w Sandra Jean Olson, MSc,z Dina Leita˜o, BSc,wy Fernando Carlos Schmitt, MD, PhD,wy and Helenice Gobbi, MD, PhD* chemistry may be used reliably as a primary methodology for Abstract: There is an increasing clinical demand for HER2 evaluating HER2; however, the use of polyclonal antibodies analysis in breast cancer, especially since the release of may not be adequate to assess HER2 overexpression. CB11, trastuzumab. The authors assessed the ability of immunohis- regardless of the manufacturer (Biogenex or Novocastra), tochemistry to detect HER2 overexpression in invasive mam- showed better concordance with FISH (kappa = 0.83) than mary carcinomas (IMC) using five antibodies. Paraffin- did the polyclonal antibodies. embedded samples of 86 IMCs (T2N0) were used to compare Key Words: breast cancer, HER2, C-erbB-2, immunohistochemi- the immunohistochemical overexpression of HER2 using two stry, fluorescence in situ hybridization polyclonal antibodies (HercepTest [DAKO] and A0485 [DAKO]) and three monoclonal antibodies (CB11 from two (Appl Immunohistochem Mol Morphol 2006;14:103–108) different laboratories, Biogenex and Novocastra, and 4D5 [Genentech]). All immunostainings were scored according to the FDA-approved HercepTest recommendations. The Her- rognostic and predictive factors
Applied Immunohistochemistry & Molecular Morphology – Wolters Kluwer Health
Published: Mar 1, 2006
Read and print from thousands of top scholarly journals.
Already have an account? Log in
Bookmark this article. You can see your Bookmarks on your DeepDyve Library.
To save an article, log in first, or sign up for a DeepDyve account if you don’t already have one.
Copy and paste the desired citation format or use the link below to download a file formatted for EndNote
Access the full text.
Sign up today, get DeepDyve free for 14 days.
All DeepDyve websites use cookies to improve your online experience. They were placed on your computer when you launched this website. You can change your cookie settings through your browser.